News | August 12, 2024
Wockhardt Q1 FY25 revenue up 14%
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Decision on EU marketing authorisation for this population expected by September 2024
Subscribe To Our Newsletter & Stay Updated
